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A B S T R A C T
Increasing evidence suggests that small oligomers are the principal neurotoxic species of tau in Alzheimer's
disease and other tauopathies. However, mechanisms of tau oligomer-mediated neurodegeneration are poorly
understood. The transience of oligomers due to aggregation can compromise the stability of oligomers prepared
in vitro. Consequently, we sought to develop an eﬃcient method which maintains the stability and globular
conformation of preformed oligomers. This study demonstrates that labeling a single-cysteine form of the pro-
aggregant tau four-repeat region (K18) with either Alexa Fluor 488-C5-maleimide or N-ethylmaleimide in re-
ducing conditions stabilizes oligomers by impeding their further aggregation. Furthermore, the use of this ap-
proach to study the propagation of labeled extracellular tau K18 oligomers into human neuroblastoma cells and
human stem cell-derived neurons is described. This method is potentially applicable for preparing stabilized
oligomers of tau for diagnostic and biomarker tests, as well as for in vitro structure-activity relationship assays.
1. Introduction
The gradual intracellular accumulation of tau aggregates into neu-
roﬁbrillary tangles (NFTs) is a clinical hallmark for diagnosing and
staging Alzheimer's disease (AD) [1]. Nonetheless, tau pathology likely
develops several years prior to symptom onset [2]. Indeed, cell death
and synaptic lesions have been observed independent of NFT formation
[3,4], prompting a need for tau biomarkers that better correlate with
disease onset and progression [5]. Increasing evidence suggests that the
activities of low molecular weight (LMW) oligomers, formed during the
early stages of tau aggregation, most likely associate with neurotoxicity
that leads to AD [6–8]. For example, tau oligomers induce mitochon-
drial, synaptic and memory defects [7] while insoluble ﬁlaments have
been postulated to provide neuroprotective functions by sequestering
toxic oligomers into inert ﬁlaments [9]. Many biochemical and toxicity
studies of tau use oligomers produced from recombinant sources due to
their ability to replicate important aggregative and pathophysiological
eﬀects of brain-derived tau oligomers [10–12]. However, the transient
formation and subsequent aggregation of LMW tau oligomers present a
daunting challenge for their preparation and characterization. Several
tau oligomer preparation protocols, including those which have sought
to address some of the existing diﬃculties, have been described
[13–16]. Nonetheless, a critical persisting challenge is the stability of
the resulting oligomers. For example, oligomeric forms of the central
nervous system-speciﬁc full length (2N4R) tau isoform prepared by
seeding monomer aggregation with preformed alpha synuclein or
amyloid beta oligomers lose their stability and aggregate into ﬁlaments
within 48 h of incubation [15]. This suggests that oligomers prepared in
vitro are unstable and are prone to further aggregation, which may
compromise experimental outcomes and reproducibility due to the
distinct conformations that tau protein adopts at diﬀerent stages of the
aggregation process [17,18]. This instability has previously been de-
monstrated for amyloid beta, another AD-linked protein, which is
capable of undergoing detectable aggregation even when stored at an
ultra-low temperature (−80 °C) for long periods [19]. This suggests
that instability is a major problem of the two most-characterized AD-
associated proteinopathic proteins when prepared in vitro.
Tau aggregation occurs by two known mechanisms, namely: (i)
cysteine-dependent polymerization through intermolecular disulﬁde
bonding [20,21], and (ii) cysteine-independent polymerization, occur-
ring through the hexapeptide motifs (275VQIINK280, 306VQIXXK311 and
337VEVKSE342) and non-covalent bonding [22–25]. Although either
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mechanism would in principle be suﬃcient, aggregation eﬃciency is
increased in the presence of both [21]. In this study, it was hypothe-
sized that labeling cysteine residues in tau monomers would extend the
stability of the oligomers formed by blocking cysteine-dependent ag-
gregation. Since maleimide irreversibly binds cysteine residues, it was
postulated that eﬃcient labeling of cysteine residues (Fig. 1) would
generate stable tau oligomers. Here, a simple approach of preparing
stable LMW tau oligomers by labeling cysteine residues with commer-
cially available derivatives of maleimide, namely Alexa Fluor 488-C5-
maleimide (AF-maleimide) and N-ethylmaleimide (NEM), is described.
Furthermore, the application of the ﬂuorescence property of AF-mal-
eimide-labeling to study the uptake of tau K18 oligomers by SH-SY5Y
cells and human induced pluripotent stem cell (hiPSC)-derived neurons
is described.
2. Materials and methods
2.1. Molecular biology and protein puriﬁcation
The pProEx-HTa-Myc-K18 plasmid used for the recombinant ex-
pression of tau K18 was used as previously described [26]. Cysteine
modiﬁcations (C291A, C322A, I260C) were introduced into the en-
coded protein to prevent potential functional interference of the mal-
eimide label. Site directed mutagenesis was performed and veriﬁed as
previously described [26]. 6xHis/c-Myc-tagged K18 was transformed
into and expressed in BL21 (DE3)*pRosetta cells and the expressed
protein puriﬁed using immobilized metal aﬃnity chromatography fol-
lowing a previously-described protocol [26].
2.2. Preparation of labeled tau K18 oligomers
Puriﬁed tau K18 was treated with 5× molar excess of tris(2-car-
boxyethyl)phosphine (TCEP) for 1 h, and then with 4× molar excess
AF-maleimide (#A10254, Molecular Probes) or NEM (#23030, Thermo
Scientiﬁc) overnight, in the presence of 10mM sodium phosphate
buﬀer pH 7.4. The protein was diluted in buﬀer to a ﬁnal concentration
of 55 μM. Free ﬂuorophore and reducing agent were removed by ex-
tensive dialysis against dialysis buﬀer (50mM Tris HCl pH 7.5, 100mM
NaCl) in a Slide-A-Lyzer™ MINI Dialysis device (10 K MWCO; Thermo
Scientiﬁc), with the reservoir perforated and placed in a container large
enough to accommodate a 2 L volume of buﬀer. The buﬀer was changed
every 2 h for 10 h. Labeling was conﬁrmed with non-denaturing sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) fol-
lowed by ultraviolet light exposure. Labeling eﬃciency was measured
spectrophotometrically using Beer's law and the molar extinction
coeﬃcient of 72,000/cm/M for AF-maleimide. Unlabeled control
samples were prepared identically except that equal volume of 10mM
sodium phosphate buﬀer pH 7.4 was used in place of the maleimide
label. The entire labeling process was performed either at 4 °C or at
room temperature (RT).
2.3. Transmission electron microscopy (TEM)
Formvar/carbon-coated 300-mesh copper grids (#S162, Agar sci-
entiﬁc, UK) were glow-discharged using the ELMO system from
Cordouan Technologies. Five microliters of labeled or unlabeled K18
preparations were pipetted onto the grid and allowed to bind for 1min.
Excess samples were removed with a strip of ﬁlter paper, and 5 μl of 2%
uranyl acetate added for 1min. After removing the excess stain with a
strip of ﬁlter paper, the grids were imaged using a JEOL-2100F trans-
mission electron microscope.
2.4. Dot blotting
Each of the labeled and unlabeled control samples (27.5 μM) was
mixed with 125 μM heparin, and incubated at 37 °C in an Eppendorf
Mastercycler gradient thermocycler for 48 h. Two microliter aliquots
were spotted onto a piece of nitrocellulose membrane, air dried,
blocked with 10% non-fat milk in phosphate buﬀered saline (PBS)
containing 0.05% Tween for 30min at RT, and subsequently washed
ﬁve times with 10% Tris buﬀered saline (TBS)-Tween. The membrane
was incubated for 2 h with primary antibody (total tau #A0024, Dako
or T22, Merck) and washed ﬁve times with 10% TBS-Tween. The
membrane was then treated with secondary antibody (anti-rabbit im-
munoglobulin G; 31450, Thermoﬁsher) for 2 h. Antibodies were used at
1:1000 dilutions in the PBS-Tween buﬀer. Thereafter, the membrane
was washed ﬁve times as previously, developed with an electro-
chemiluminescent detection kit (Amersham), exposed to an X-ray ﬁlm
for 2min and the blots developed in an AGFA Curix 60 processor (Agfa
Healthcare, Greenville, SC, USA). Blot intensities were analyzed using
ImageJ and the non-parametric data statistically compared with the
Mann-Whitney test in GraphPad Prism 7 at the 95% conﬁdence in-
terval.
Fig. 1. Schematic illustration of mal-
eimide conjugation to the tau K18 pro-
tein. (A) Molecular structure of AF-mal-
eimide, as provided by the vendor [42]. (B)
Molecular structure of NEM. (C) Illustration
of the reaction of the maleimide functional
group of AF-maleimide with the sulfhydryl
group of tau K18 to produce a stable thioe-
ther conjugate. (D) Illustration of the spe-
ciﬁc binding of NEM with the sulfhydryl
group of tau K18 to produce a tau K18-NEM
conjugate.
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2.5. SH-SY5Y cell culture
SH-SY5Y cells were purchased from Sigma Aldrich UK (#94030304)
and maintained on 1:1 minimal essential medium (MEM)/F12 Ham
medium containing 1% L-Glutamine, 15% foetal bovine serum, and 1%
antibiotic antimycotic acid (10,000 units penicillin, 10mg streptomycin
and 25 μg amphotericin B). All reagents were obtained from Sigma
Aldrich. Cells between passages two and ten were used for all experi-
ments. The cells were seeded at 200,000 cells/ml in CellView™
Advanced Tissue Culture dishes (#627975, Greiner Bio-One) in the
presence of AF-maleimide-labeled tau K18 oligomers dissolved in the
culture medium to 5 μM. Following 24 h incubation at 37 °C, 5% CO2,
the spent medium was removed, the cells washed with warm PBS and
fresh tau-free medium containing 2 μM Hoechst 33342 (#H21492,
Molecular Probes) and CellMask Deep Red (1:1000 dilution, #C10046,
Thermoﬁsher). Confocal microscopy imaging of internalized tau was
performed after 30min incubation at 37 °C, 5% CO2 using an LSM 710
microscope (Leica).
2.6. hiPSC-derived cortical neurons
Neural precursor cells (#ax0016) from cord blood CD34 + cells of a
healthy, newborn female donor were purchased from Axol Bioscience,
Cambridge, UK. Tissue culture grade 12-well plates (Corning, New
York, USA) were pre-coated with 250 μl/cm2 ReadySet reagent (Axol
Bioscience), incubated at 37 °C, 5% CO2 for 45min and rinsed four
times with double distilled water. Following this, Surebond reagent
(Axol Bioscience) was diluted in Dulbecco's PBS (DPBS), added to the
plates at 200 μl/cm2 and incubated at 37 °C, 5% CO2 to equilibrate for
1 h. Next, stem cells were seeded at a low density (25,000 cells/cm2) on
plasma-cleaned 13mm glass coverslips, incubated at 37 °C, 5% CO2 and
media changed every other day with Axol Neural Maintenance Medium
kit (#ax0031, Axol Bioscience) for 14–16 days prior to using the cells
for experiments. Neuronal diﬀerentiation was monitored using phase
contrast images obtained periodically with an EVOS XL Core Imaging
System (Life Technologies) and the expression of neuron-speciﬁc mar-
kers monitored by immunohistochemistry (data not shown). Tau oli-
gomers were diluted to 5 μM in Axol Neural Maintenance medium,
supplied to neurons and then incubated for 24 h at 37 °C, 5% CO2. After
removing the spent medium, the neurons were washed with DPBS, and
new medium added.
Neurons were then ﬁxed for 30min with 4% paraformaldehyde,
washed two times with DPBS, and rinsed with permeabilizing solution
(DPBS containing 0.2% Triton). Afterwards, the ﬁxed neurons were
incubated for 1 h in blocking buﬀer (DPBS with 0.2% Triton and 2%
BSA). This was followed by another 1 h incubation in the blocking
buﬀer containing primary antibody and Hoechst. Excess antibody was
removed by washing thrice with blocking buﬀer only for 5min each
time. Subsequently, the neurons were incubated in blocking buﬀer
containing secondary antibody for 1 h, and the blocking buﬀer wash
steps repeated. Next, the slides were rinsed with distilled water and
dropped into ProLong Gold Antifade mounting medium (#P36934,
ThermoFisher Scientiﬁc). Neurons were imaged with a Leica STP 6000
confocal microscope after at least 24 h of curing.
3. Results and discussion
This study used the K18 fragment (tau microtubule (MT) binding
region; residues 244–372), since a demonstration of oligomer stability
for this aggregation-prone functional tau region would in principle
make the method applicable to the full-length isoforms which are less
aggregation-prone [27] and may therefore be easier to stabilize. Due to
their close proximity to residues that directly bind MTs [28], the two
native cysteine residues in tau K18 were modiﬁed to alanine and a new
one introduced at the N-terminus of the MT-binding region (see the
Materials and Methods section). This approach was to ensure eﬃcient
labeling of a single cysteine residue without potential interference of
MT binding [17,29,30].
The K18 tau construct was cloned into pProEx, transformed into
BL21 (DE3) Escherichia coli, expressed, puriﬁed and biochemically
characterized as described [26]. Oligomers were prepared by initially
treating freshly-puriﬁed proteins with the reducing agent TCEP for 1 h
to ensure all proteins were monomeric. Thereafter, the exposed sulf-
hydryl groups were labeled with AF-maleimide and the reaction al-
lowed to proceed at 4 °C overnight followed by extensive dialysis to
remove excess dye and TCEP. This “monomerization-labeling-oligo-
merization” strategy ensured accessibility of the labeling site to the
maleimide dye. The overnight incubation in cold conditions allowed for
limited aggregation of labeled monomers into LMW oligomers. Control
samples labeled without TCEP treatment lacked the uniform oligomer
distribution observed in those TCEP-treated before labeling (Fig. 2).
The labeled proteins aggregated into globular, LMW oligomers (Fig. 3),
akin to what is found in the brains of AD patients [6] and those reported
from other recombinant tau oligomerization protocols [15]. No dis-
cernible diﬀerence in oligomerization patterns was observed between
the labeled and unlabeled proteins (Fig. 3) as all samples were capable
of forming oligomers. However, oligomers assembled from unlabeled
tau K18 were unstable as explained below.
To test the hypothesis that cysteine labeling interferes with tau
aggregation, the AF-maleimide labeled oligomers and unlabeled con-
trols were challenged with the aggregation inducer heparin and heated
at 37 °C without shaking for 48 h. After incubation, aliquots were taken
from each sample following quick mixing and analyzed by negative-
stain TEM. The labeled proteins existed mostly as globular oligomers
(Fig. 4A), appeared mainly trimeric/tetrameric in distribution (Fig. 2A),
and were of similar structure as those imaged prior to heparin and heat
treatment (Fig. 3B). By contrast, the unlabeled protein underwent fur-
ther aggregation to form mature insoluble ﬁlaments, via intermediate
protomers and early-stage ﬁlaments (Fig. 4B). These results indicate
that AF-maleimide labeling stabilizes tau oligomers and prevents their
aggregation and conformational change into paired helical ﬁlaments.
Fig. 2. Representative non-denaturing SDS-PAGE images demonstrating
the outcome of AF-maleimide labeling of tau K18 in reducing and non-
reducing conditions. Migration of tau K18 labeled with AF-maleimide with
(A) or without (B) prior TCEP treatment. The ﬁgures show representative
(n=3) non-denaturing SDS-PAGE analysis of tau aggregate patterns in the two
labeling methods.
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Performing the reaction under cold conditions appeared critical to
the success of the new method. Contrary to the dominance of globular
oligomers when labeled at 4 °C (Figs. 3 and 4), a mixture of globular
oligomers and ﬁbrils was observed when the reaction was performed at
RT (Fig. S1). This phenomenon may be explained by the higher labeling
eﬃciency at 4 °C compared to at RT (97% and 82.5% respectively);
there is a much higher proportion of unlabeled starting material at RT
capable of aggregating into ﬁbrils. This data is in agreement with
previous reports showing high AF-maleimide labeling eﬃciencies at
4 °C [31,32], and also explains why ﬁbrils can be detected among tau
proteins labeled at RT or 37 °C [29,30].
Next, we asked if the observed oligomer-stabilizing property of AF-
maleimide was shared by other maleimide derivatives. For this reason,
the alkylating agent NEM which reacts in a similar mechanism as AF-
maleimide with sulfhydryls to form stable thioesters was tested. NEM
labeling of tau K18 was performed as described for AF-maleimide. To
test their stability, the formed oligomers were treated with heparin,
incubated at 37 °C for 48 h and thereafter characterized by TEM. It was
observed that, like AF-maleimide, NEM labeling stabilized tau oligo-
mers also appeared to block further aggregation into ﬁlaments (Fig. 5A
and B).
Subsequently, the eﬀect of maleimide labeling on the conformation
Fig. 3. Structural characterization of tau K18 oligomers stabilized by labeling with maleimide derivatives. Representative TEM micrographs of globular tau
K18 oligomers prepared: (A) without labeling, (B) with AF-maleimide labeling, or (C) with NEM labeling. Scale bars= 50 nm for all images.
Fig. 4. Labeling with AF-maleimide stabilizes tau K18 oligomers. (A) Representative electron micrographs of AF-maleimide-labeled tau K18 structures identiﬁed
after co-incubation with heparin at 37 °C for 48 h. Figures A(i) and A(ii) show globular oligomers with diﬀerent degrees of negative staining. (B) Representative TEM
micrographs of aggregates identiﬁed for the unlabeled control samples treated similarly to the test samples. Globular oligomers (i), protomers (ii), short and mature
ﬁbrils (iii and iv respectively) were observed, suggesting heparin-induced structural transition to form ﬁbrils. n= 2, with images taken from at least 5 diﬀerent areas
of each TEM grid. Scale bars= 100 nm for all images.
T.K. Karikari et al. Analytical Biochemistry 566 (2019) 67–74
70
of tau K18 oligomers was investigated. The immunoreactivity of oli-
gomer preparations labeled with AF-maleimide or NEM was probed
with an oligomer conformation-speciﬁc antibody (T22) and a total tau
antibody (A0024, Dako) as a control in dot blotting experiments.
Oligomers labeled using either method gave near-identical total tau
reactivity to the unlabeled control (Figs. 6 and 7). However, the labeled
proteins were consistently less reactive to the T22 antibody (Mann
Whitney test, p < 0.05 in both cases; Figs. 6 and 7). This suggests that
the conformation of the unlabeled tau K18 oligomers recognized by the
T22 antibody was altered by the maleimide labeling. A few reasons
could have accounted for this reduced recognition. Firstly, the
maleimide labels may have masked the antibody epitope thereby re-
ducing accessibility and binding of the antibody. A similar outcome has
recently been reported from a pharmacological inhibition of tau oli-
gomer aggregation where binding of the phenothiazine compound
Azure C also reduced T22 reactivity [33]. Secondly, the antibody pre-
ferably recognises larger oligomers over LMW oligomers, such as those
found in the labeled samples. As the unlabeled samples aggregated
further into ﬁbrils, it can be postulated that they may have consisted of
larger pools of higher molecular weight oligomers which would be re-
sponsible for their stronger reactivity. T22 is thought to selectively
recognize non-ﬁbrillar tau oligomers [8] but it may not be able to
Fig. 5. NEM labeling stabilizes tau K18 oligomers in their globular conformation. NEM-labeled and unlabeled control tau K18 samples were each incubated
with heparin at 37 °C for 48 h, and aliquots analyzed using negative-stain TEM. (A) Representative TEM micrographs of NEM-labeled tau K18 aggregates. The
globular nature of these non-ﬁbrillar aggregates in A(i) and A(ii) suggests oligomer stabilization. (B) Representative TEM micrographs of endpoint samples de-
monstrating the aggregation of unlabeled tau K18 into oligomers, protomers, short and mature ﬁbrils. n= 2, with images taken from at least 5 diﬀerent areas of each
grid. Scale bars= 100 nm for all images.
Fig. 6. Immunological analysis of the
conformation of AF-maleimide-labeled
tau K18 oligomers using dot blotting. (A)
Representative dot blot data for the re-
activity of labeled and unlabeled tau K18 to
two tau antibodies (A0024, top panel) and
T22 (bottom panel). (B) Semi-quantitative
analysis of dot blot intensity using Image J.
UNL = unlabeled; MAL = AF-maleimide
labeled. Mann Whitney test, * = p < 0.05,
ns = not signiﬁcant (n = 4). Data expressed
as mean ± standard deviation.
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discriminate between oligomers of diﬀerent sizes which share the same
conformational epitope. The stronger immuno-reactivity recorded for
the unlabeled samples may be due to diﬀerences in non-ﬁbrillar ag-
gregated proteins compared to the labeled (Figs. 6 and 7). Thirdly, since
the T22 antibody can also cross-react with ﬁbrils [8], the presence of
ﬁbrils in the unlabeled samples may have increased the reactivity of the
T22 antibody in the unlabeled samples. As the only diﬀerence between
the labeled and the unlabeled tau K18 samples was the extent of ag-
gregation as evidenced by TEM analysis, it can be concluded that AF-
maleimide labeling reduces reactivity of tau K18 oligomers to the T22
conformation-dependent antibody, which may be due to their restricted
aggregation. This ﬁnding along with those of others [32] suggests care
should be taken when assessing oligomerization using the T22 antibody
alone.
A mechanism proposed for the propagation of AD pathology is the
transmission of toxic tau proteins from one neuron to the other in
speciﬁc brain regions [34–36]. A critical step in this inter-neuronal
transmission model is the uptake of extracellular tau into neighboring
neurons, followed by their interaction with endogenous proteins and
subsequent release of the resulting aggregates to initiate new inter-
nalization cycles [34–36]. For better understanding of the molecular
cascade of events occurring in this process, real-time microscopic vi-
sualization of live cells treated with tau is necessary. As oligomers are
thought to be a crucial species regulating the inter-neuronal transmis-
sion of tau pathology [6,8,10,11], the molecular ﬂuorescence property
of AF-maleimide was used to study the internalization of stabilized
extracellular tau K18 oligomers into cultured SH-SY5Y human neuro-
blastoma cells. AF-maleimide oligomers were prepared as described
above, diluted in extracellular medium to 5 μM ﬁnal concentration,
supplied exogenously to cultured cells and incubated for 24 h.
Fig. 7. Dot blot analysis of the con-
formation of NEM-labeled tau K18 oligo-
mers. (A) Representative dot blot data for
the immuno-reactivity of labeled and un-
labeled tau K18 to two tau antibodies
(A0024, top panel) and T22 (bottom panel).
(B) Semi-quantitative analysis of dot blot
intensity using Image J. UNL = unlabeled;
NEM = NEM labeled. Mann Whitney test,
* = p < 0.05, ns = not signiﬁcant (n = 4).
Data expressed as mean ± standard de-
viation.
Fig. 8. Extracellularly-applied tau K18 oligomers are internalized by SH-SY5Y neuroblastoma cells and hiPSC-derived neurons. (A) Internalization of AF-
maleimide-labeled tau K18 oligomers in SH-SY5Y neuroblastoma cells. (B) Internalization of extracellular oligomers was also studied in hiPSC-derived neurons,
revealing their localization both in neurites and the cell soma. Scale bars= 10 μm for all images.
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Subsequently, the spent medium was removed, the cells washed with
warm phosphate buﬀered saline to remove non-internalized tau and
new tau-free medium containing nuclear and cell membrane markers
added. The internalized tau was then visualized using confocal micro-
scopy. Remarkably, internalization of ﬂuorescent extracellular tau was
observed, with cells containing these internalized proteins exhibiting
diverse morphological phenotypes: in some cells diﬀused cytoplasmic
distribution of labeled protein was observed, with more localized
punctate staining in other cells (Fig. 8A). These phenotypes were si-
milar to those reported for labeled tau K18 internalized in the same
neuroblastoma cell line [30], as well as other human cell lines [37]. To
extend the use of these ﬂuorescently labeled oligomers toward a more
physiologically-relevant neuronal model, hiPSC-derived cortical neu-
rons were prepared and seeded with 5 μM extracellular tau oligomers.
Following 24 incubation, the neurons were ﬁxed using paraformalde-
hyde. Maximum projection of z-stack confocal microscopy images re-
vealed that tau oligomer internalization likely occurs by endocytosis (as
oligomers were encapsulated by the vesicular marker FM4-64®) and
that the inclusions accumulated both in the cell soma and neurites,
hence providing insights into the subcellular localization of tau oli-
gomer inclusions in addition to their morphological phenotypes
(Fig. 8B). Together, these ﬁndings demonstrate that maleimide stabi-
lization oﬀers a unique strategy for the characterization of cellular in-
ternalization of tau oligomers and to screen for therapeutic agents
against this disease-relevant process.
Here, we have demonstrated that eﬃcient labeling of tau K18 with
AF-maleimide or NEM provides the advantage of stabilizing the
resulting oligomers. Interestingly, a recent study by Chen et al. (2018)
has corroborated our ﬁndings, showing that NEM labeling of the single
cysteine residue at amino acid position 322 of the shortest tau isoform
in the adult human brain (0N3R) prevents its H2O2-induced aggregation
[38]. Our proposed strategy (Fig. 9) ensures that preformed tau oligo-
mers remain in their desired authentic oligomeric state for extended
periods of time, oﬀering an exceptional opportunity to advance
downstream investigations into the biochemical, biophysical and neu-
robiological aspects of the association between tau aggregation and
neurodegeneration. Moreover, the method is simple, time-eﬃcient and
does not require expensive pre- and post-treatment stages. The pro-
posed approach is potentially applicable to brain-derived tau oligomers,
and could support studies of mechanistic and conformational changes
in tau oligomers that may alter the protein's neurotoxicity and drug-
reactivity proﬁles. Additionally, the method can likely be extended to
other proteinopathic proteins containing cysteine residues, such as
huntingtin and cysteine-containing amyloid beta [39]. We have applied
this approach to obtain novel insights into the subcellular internaliza-
tion and neuronal transmission of exogenous tau K18. This has allowed
an analysis of the eﬀects of tau mutant variants implicated in diseases
such as frontotemporal dementia on the protein's neuronal inter-
nalization. Our results indicate that this method provides a quick and
reliable approach of monitoring cellular internalization of exogenous
proteins in real time, and therefore oﬀers an advantage over other
ﬂuorescent tags especially for small proteins like tau K18. Furthermore,
the neuronal uptake and secretion of extracellular tau oligomers are
thought to be regulated by protein-cell membrane interactions, details
of which are still unclear [40,41]. This oligomer stabilization strategy
oﬀers a straightforward approach to study conformational and ag-
gregation dynamics of protein-membrane interactions both at the single
and bulk molecular levels using ﬂuorescent spectroscopy and cell
biology techniques. Additionally, stabilized oligomers are good im-
munogen candidates for antibody production against tau oligomer-
targeted immunotherapy.
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Abbreviations
AD Alzheimer's disease
AF-maleimide Alexa Fluor 488-C5-maleimide
DPBS Dulbecco's phosphate buﬀered saline
Fig. 9. Schematic illustration of the facile method of tau oligomer stabi-
lization described in this study. The method involves ﬁrst treating highly-
puriﬁed monomers with the reducing agent TCEP to monomerize apparent
oligomers. Monomers are then labeled overnight with either maleimide deri-
vative (AF-maleimide or NEM), followed by removal of excess ﬂuorophore by
dialysis. Labeled oligomers can then be characterized using an array of bio-
chemical and biophysical tools, including non-denaturing SDS-PAGE, dot/
Western blotting and TEM. Oligomer stabilization can be studied by inducing
aggregation with heparin and studying the structures and conformation of the
aggregates formed by TEM and dot blotting respectively, or by similar techni-
ques.
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LMW low molecular weight
MT microtubule
NEM N-ethylmaleimide
NFT neuroﬁbrillary tangle
PBS phosphate buﬀered saline
RT room temperature
SDS-PAGE sodium dodecyl sulfate – polyacrylamide gel electrophor-
esis
TCEP tris(2-carboxyethyl)phosphine
TBS Tris buﬀered saline
TEM transmission electron microscopy
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